×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PCRX – pacira biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PCRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
10:14 am
pcrx
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee [Yahoo! Finance]
Low
Report
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee [Yahoo! Finance]
11/14
10:05 am
pcrx
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Low
Report
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
11/12
10:45 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $25.00 to $17.00. They now have an "equal weight" rating on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $25.00 to $17.00. They now have an "equal weight" rating on the stock.
11/12
08:00 am
pcrx
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Medium
Report
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
11/8
08:46 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
11/7
12:32 pm
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Royal Bank of Canada from $15.00 to $16.00. They now have a "sector perform" rating on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Royal Bank of Canada from $15.00 to $16.00. They now have a "sector perform" rating on the stock.
11/7
11:47 am
pcrx
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth [Yahoo! Finance]
Low
Report
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth [Yahoo! Finance]
11/7
02:31 am
pcrx
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
Medium
Report
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/6
04:02 pm
pcrx
Form 10-Q Pacira BioSciences, Inc. For: Sep 30
Low
Report
Form 10-Q Pacira BioSciences, Inc. For: Sep 30
11/6
04:01 pm
pcrx
Form 8-K Pacira BioSciences, Inc. For: Oct 31
Low
Report
Form 8-K Pacira BioSciences, Inc. For: Oct 31
11/5
04:42 pm
pcrx
Form 4 Pacira BioSciences, Inc. For: Nov 01 Filed by: Cross Shawn
Low
Report
Form 4 Pacira BioSciences, Inc. For: Nov 01 Filed by: Cross Shawn
10/23
06:55 pm
pcrx
Form 3 Pacira BioSciences, Inc. For: Oct 21 Filed by: Cross Shawn
Low
Report
Form 3 Pacira BioSciences, Inc. For: Oct 21 Filed by: Cross Shawn
10/21
08:05 am
pcrx
Form 8-K Pacira BioSciences, Inc. For: Oct 16
Low
Report
Form 8-K Pacira BioSciences, Inc. For: Oct 16
9/27
08:02 am
pcrx
Form 8-K Pacira BioSciences, Inc. For: Sep 26
Low
Report
Form 8-K Pacira BioSciences, Inc. For: Sep 26
9/13
08:30 pm
pcrx
Form 4 Pacira BioSciences, Inc. For: Sep 13 Filed by: GAUGLER DARYL
Medium
Report
Form 4 Pacira BioSciences, Inc. For: Sep 13 Filed by: GAUGLER DARYL
9/13
10:18 am
pcrx
Form 144 Pacira BioSciences, Inc. Filed by: GAUGLER DARYL
Low
Report
Form 144 Pacira BioSciences, Inc. Filed by: GAUGLER DARYL
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/17
Pacira Biosciences Inc (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Northland Securities. They now have a $50.00 price target on the stock.
13.0%
3/23 Pacira Biosciences Inc (NASDAQ: PCRX) had its price target lowered by analysts at Piper Sandler from to . 6.6%
3/12 Form 4 Pacira BioSciences, Inc. For: Mar 11 Filed by: WINSTON ROY 6.0%
10/3 Pacira Biosciences Inc (NASDAQ: PCRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.7%
2/10 Form SC 13G/A Pacira BioSciences, Inc. Filed by: BlackRock Inc. 5.0%
6/6 Form 4 Pacira BioSciences, Inc. For: Jun 05 Filed by: Brege Laura 4.6%
4/30 Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020 4.5%
4/24 Form DEF 14A Pacira BioSciences, Inc. For: Jun 08 3.6%
3/17 Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.5%
11/7 Pacira Biosciences Inc (NASDAQ: PCRX) had its "hold" rating re-affirmed by analysts at Cowen Inc. They now have a $41.00 price target on the stock. 3.3%
3/23 Pacira Biosciences Inc (NASDAQ: PCRX) had its price target lowered by analysts at Piper Sandler from to . 6.6%
3/12 Form 4 Pacira BioSciences, Inc. For: Mar 11 Filed by: WINSTON ROY 6.0%
10/3 Pacira Biosciences Inc (NASDAQ: PCRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.7%
2/10 Form SC 13G/A Pacira BioSciences, Inc. Filed by: BlackRock Inc. 5.0%
6/6 Form 4 Pacira BioSciences, Inc. For: Jun 05 Filed by: Brege Laura 4.6%
4/30 Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020 4.5%
4/24 Form DEF 14A Pacira BioSciences, Inc. For: Jun 08 3.6%
3/17 Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.5%
11/7 Pacira Biosciences Inc (NASDAQ: PCRX) had its "hold" rating re-affirmed by analysts at Cowen Inc. They now have a $41.00 price target on the stock. 3.3%
TOP News Decliners
3/20
Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating.
-12.1%
3/23 Pacira Biosciences Inc (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $65.00 to $56.00. They now have an "outperform" rating on the stock. -9.6%
3/9 Pacira BioSciences to Present at the 2020 Barclays Global Healthcare Conference -6.8%
2/20 Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.6%
8/8 Q2/2019 6/30/2019 EPS 0.410 ZacksConsensus 0.140 ActVsEst 0.270 - Beat -3.4%
9/24 Pacira BioSciences Set to Join S&P SmallCap 600 -3.3%
6/5 Form 4 Pacira BioSciences, Inc. For: Jun 03 Filed by: Scranton Richard -3.2%
2/21 Form 10-K Pacira BioSciences, Inc. For: Dec 31 -3.1%
9/30 Form SC 13G Pacira BioSciences, Inc. Filed by: INTEGRATED CORE STRATEGIES (US) LLC -3.0%
1/7 EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients -2.9%
3/23 Pacira Biosciences Inc (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $65.00 to $56.00. They now have an "outperform" rating on the stock. -9.6%
3/9 Pacira BioSciences to Present at the 2020 Barclays Global Healthcare Conference -6.8%
2/20 Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.6%
8/8 Q2/2019 6/30/2019 EPS 0.410 ZacksConsensus 0.140 ActVsEst 0.270 - Beat -3.4%
9/24 Pacira BioSciences Set to Join S&P SmallCap 600 -3.3%
6/5 Form 4 Pacira BioSciences, Inc. For: Jun 03 Filed by: Scranton Richard -3.2%
2/21 Form 10-K Pacira BioSciences, Inc. For: Dec 31 -3.1%
9/30 Form SC 13G Pacira BioSciences, Inc. Filed by: INTEGRATED CORE STRATEGIES (US) LLC -3.0%
1/7 EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients -2.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: